Login to Your Account

Gouda Chiesi? Cerespir SPA outline submitted for phase III AD effort

By Randy Osborne
Staff Writer

Wednesday, July 1, 2015

Cerespir Inc. submitted an SPA plan for the phase III trial with CSP-1103 to treat mild cognitive impairment Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription